Author

Elie Traer

Oregon Health & Science University - Cited by 5,554 - cancer biology - kinase inhibitors - resistance - apoptosis

Biography

Dr. Traer completed a fellowship in hematology/oncology from Oregon Health & Science University. He received his M.D./Ph.D. from the University of Texas Southwestern Medical School and completed a residency in internal medicine at Oregon Health & Science University.
Title
Cited by
Year
Proteogenomic and metabolomic characterization of human glioblastoma
LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ...Cancer cell 39 (4), 509-528. e20, 2021202
256
2021
Proteogenomic characterization of endometrial carcinoma
Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ...Cell 180 (4), 729-748. e26, 2020202
243
2020
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ...Cancer cell 39 (3), 361-379. e16, 2021202
160
2021
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ...Nature medicine 26 (12), 1852-1858, 2020202
92
2020
Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic …
AM Brunner, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...Blood 136, 1-2, 2020202
61
2020
Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS …
AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ...Blood 138, 244, 2021202
54
2021
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
SK Joshi, T Nechiporuk, D Bottomly, PD Piehowski, JA Reisz, ...Cancer Cell 39 (7), 999-1014. e8, 2021202
51
2021
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ...Cancer Cell 40 (8), 850-864. e9, 2022202
39
2022
IDH inhibitors in AML—promise and pitfalls
H McMurry, L Fletcher, E TraerCurrent Hematologic Malignancy Reports 16 (2), 207-217, 2021202
30
2021
Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms
SK Joshi, K Qian, WH Bisson, K Watanabe-Smith, A Huang, D Bottomly, ...Blood, The Journal of the American Society of Hematology 135 (), 2159-2170, 2020202
24
2020
Profile of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date
L Fletcher, SK Joshi, E TraerCancer Management and Research, 151-163, 2020202
23
2020
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
SK Joshi, JM Keck, CA Eide, D Bottomly, E Traer, JW Tyner, ...Leukemia 34 (10), 2798-2804, 2020202
14
2020
Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive …
LF Newell, T Williams, J Liu, Y Yu, Y Chen, GC Booth, RJ Knight, ...Transplantation and Cellular Therapy 27 (8), 662. e1-662. e9, 2021202
12
2021
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
CA Lachowiez, N Long, J Saultz, A Gandhi, LF Newell, B Hayes-Lattin, ...Blood Advances 7 (9), 1899-1909, 2023202
11
2023
A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance
SK Joshi, S Sharzehi, J Pittsenbarger, D Bottomly, CE Tognon, ...American journal of hematology 96 (7), E226, 2021202
10
2021
AML-190: anti-TIM-3 antibody MBG453 in combination with hypomethylating agents (HMAs) in patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia: a …
A Brunner, U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...Clinical Lymphoma Myeloma and Leukemia 20, S188-S189, 2020202
10
2020
Sabatolimab (MBG453) dose selection and dose-response analysis in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML): population pharmacokinetics (PK) modeling and …
AH Wei, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...Blood 136, 40-42, 2020202
8
2020
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
SJC Gosline, C Tognon, M Nestor, S Joshi, R Modak, A Damnernsawad, ...Clinical proteomics 19 (1), 30, 2022202
7
2022
Allogeneic hematopoietic cell transplantation outcomes of patients with R/R AML or higher-risk MDS treated with the TIM-3 inhibitor MBG453 (sabatolimab) and hypomethylating agents
Allogeneic hematopoietic cell transplantation outcomes of patients with R/R AML or higher-risk MDS treated with the TIM-3 inhibitor MBG43 (sabatolimab) and hypomethylating agentsAM Brunner, E Traer, N Vey, S Scholl, N Tovar, K Porkka, R Narayan, ...Blood 138, 3677, 2021202
5
2021
ASTX727-03: phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk myelodysplastic syndromes (LR-MDS) patients
ASTX727-0: phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk myelodysplastic syndromes (LR-MDS) patientsG Garcia-Manero, K Bachiashvili, H Amin, E Traer, DA Pollyea, ...Blood 140 (Supplement 1), 1112-1114, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=Bgi641sAAAAJ&hl=en

Cited by
Citations 5554
h-index 30
i10-index 43
Recommended Journals
Open Access Journals